Medications used to treat idiopathic inflammatory myopathy in the EuroMyositis Registry
| % within each diagnostic subtype with recorded use of each medication | Dermatomyositis (n=353) | Polymyositis (n=206) | Antisynthetase syndrome (n=184) | Connective tissue disease-overlap myositis (n=134) | Inclusion body myositis (n=47) | Immune- mediated necrotising myositis (n=50) | Juvenile dermatomyositis (n=49) |
Overall total n (% per medication)* (2613 medications in 1023 cases) |
| Glucocorticoids | 98 | 100 | 98 | 96 | 89 | 98 | 96 | 969/993 (98) |
| Disease modifying antirheumatic drugs | ||||||||
| Methotrexate | 69 | 76 | 60 | 72 | 82 | 82 | 74 | 500/704 (71) |
| Azathioprine | 44 | 52 | 60 | 51 | 35 | 59 | 57 | 311/615 (51) |
| Ciclosporin | 31 | 27 | 31 | 23 | 4 | 28 | 40 | 152/545 (28) |
| Antimalarials | 37 | 11 | 16 | 29 | 7 | 0 | 48 | 131/533 (25) |
| Mycophenolate | 17 | 20 | 31 | 29 | 24 | 13 | 33 | 119/511 (23) |
| Tacrolimus | 1 | 5 | 2 | 0 | 0 | 0 | 0 | 9/487 (2) |
| Leflunomide | 0 | 3 | 3 | 4 | 0 | 6 | 6 | 11/489 (2) |
| Biological therapies | ||||||||
| Rituximab | 6 | 4 | 14 | 7 | 2 | 12 | 0 | 72/1025 (7) |
| Other biologic† | 7 | 4 | 11 | 20 | 48 | 19 | 22 | 62/493 (13) |
| Immunomodulatory therapies | ||||||||
| IVIg | 11 | 13 | 7 | 7 | 17 | 18 | 25 | 118/1025 (12) |
| Plasma exchange | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 5/490 (1) |
| Other | ||||||||
| Cyclophosphamide | 15 | 14 | 39 | 18 | 4 | 17 | 6 | 101/520 (19) |
| Other (not specified) | 5 | 3 | 8 | 10 | 14 | 0 | 11 | 34/501 (7) |
| Topical therapies | ||||||||
| Topical glucocorticoids | 7 | 2 | 2 | 1 | 4 | 0 | 6 | 18/489 (4) |
| Topical tacrolimus | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1/485 (0) |
| Median number of recorded medications per case (IQR) | 2 (1–3) | 2 (1–3) | 3 (2–4) | 2 (2–3) | 2 (2–3) | 2 (1–3) | 2 (1–3) | two medications (IQR 1–3) |
*Some cases have received mediation from multiple categories.
†Includes antitumour necrosis factors, anakinra and abatacept.
IMNM, immune-mediated necrotising myopathy; IVIg, intravenous immunoglobulin.